PBT434 (mesylate)

PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc) . PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) [1][2].

Product Specifications

CAS Number

[2387898-69-1]

Product Name Alternative

ATH434 (mesylate)

UNSPSC

12352005

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pbt434-methanesulfonate.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N=C(CNCC)N1C)C(O)=C(Cl)C=C2Cl.O=S(O)(C)=O

Molecular Formula

C13H17Cl2N3O5S

Molecular Weight

398.26

References & Citations

[1]Finkelstein DI, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2017 Jun 28;5 (1) :53.|[2]Bailey DK, Clark W, Kosman DJ. The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells. PLoS One. 2021 Jul 26;16 (7) :e0254794.